About Akarna Therapeutics
Akarna Therapeutics is a company based in San Diego (United States) founded in 2014 was acquired by Allergan in September 2016.. Akarna Therapeutics has raised $15 million across 1 funding round from investors including Allergan, Forbion and New Science Ventures. Akarna Therapeutics operates in a competitive market with competitors including NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, Corcept and ViaCyte, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
326 people
Software Development Team
295 people
Sales and Marketing
173 people
Senior Team
76 people
Product Management Team
75 people
Human Resources and Administration
63 people
Operations Team
56 people
Data Analysis and Operations Team
47 people
Unlock access to complete
Funding Insights of Akarna Therapeutics
Akarna Therapeutics has successfully raised a total of $15M through 1 strategic funding round. The most recent funding activity was a Series B round of $15 million completed in February 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $15.0M
-
First Round
First Round
(16 Feb 2016)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2016 | Amount | Series B - Akarna Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Akarna Therapeutics
Akarna Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Allergan, Forbion and New Science Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on lifescience and healthcare sectors
|
Founded Year | Domain | Location | |
|
Early, mid, and late-stage investments are made in science sectors.
|
Founded Year | Domain | Location | |
|
Corporate-backed venture capital is focused on fintech and multiple sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Akarna Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Akarna Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Akarna Therapeutics Comparisons
Competitors of Akarna Therapeutics
Akarna Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, Corcept and ViaCyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Developer of small-molecule drugs
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of cortisol modulators for the treatment of various diseases
|
|
| domain | founded_year | HQ Location |
Cell therapy for diabetes is developed from stem cells.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Akarna Therapeutics
When was Akarna Therapeutics founded?
Akarna Therapeutics was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Where is Akarna Therapeutics located?
Akarna Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Akarna Therapeutics a funded company?
Akarna Therapeutics is a funded company, having raised a total of $15M across 1 funding round to date. The company's 1st funding round was a Series B of $15M, raised on Feb 16, 2016.
What does Akarna Therapeutics do?
Akarna Therapeutics was founded in 2014 in San Diego, United States, focusing on the biotechnology sector. Therapeutics targeting FXR, a nuclear hormone receptor in liver, intestine, kidney, and adipose tissue, are being developed for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The lead FXR agonist candidate is currently in preclinical testing, with operations centered on advancing these programs.
Who are the top competitors of Akarna Therapeutics?
Akarna Therapeutics's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
Who are Akarna Therapeutics's investors?
Akarna Therapeutics has 4 investors. Key investors include Allergan, Forbion, New Science Ventures, and Third Point Ventures.